Other Patients Sample Clauses

Other Patients. As of the Closing Date, Sellers shall prepare cutoff bxxxxxxx for all Transition Patients not covered by Section 10.13(a). Sellers shall be entitled to receive all amounts collected in respect of such cut-off bxxxxxxx. Buyers shall remit to Sellers any amounts Buyers receive after the Closing with respect to medical services rendered to such Transition Patients on or prior to the Closing Date, including any periodic interim payments or portions thereof applicable to the period on or prior to the Closing Date; and
Sample 1See All (5)
AutoNDA by SimpleDocs
Other Patients. As of the Effective Time, Sellers shall prepare and send cut-off bxxxxxxx for all patients not covered by Section 1.7(a).
Sample 1
Other Patients. As of the Effective Time, Sellers shall prepare cut-off bxxxxxxx for all patients not covered by Section 1.7(a). The cut-off bxxxxxxx shall be sent following the discharge of the patient from the Hospital.
Sample 1
Other Patients. With respect to Medicare, Medicaid, CHAMPUS and other diagnostic related group Transition Patients where cut-off billxxxx xxxnot be done at the time of Closing, the valuation of accounts receivable in respect of each Transition Patient, and the amount to be included in Net Working Capital, shall be equal to the payments to be received by Buyer after the Closing in respect of such Transition Patient, multiplied by a fraction, the numerator of which shall be the total charges for services provided by Seller to such Transition Patient, and the denominator of which shall be the sum of the total charges of all services provided to such Transition Patient by Seller and by Buyer (including charges for medicine, drugs and supplies).
Sample 1
Other Patients. For all other home healthcare patients ("Other Patients"), Lovelace and Heritage shall jointly determine the date on which Hxxxxxxx shall commence providing home healthcare services to a particular patient ("Transition Date"). Lovelace shall obtain (and deliver to Heritage prior to closing) xxxx Xxxtiva Health Services ("Gentiva") its written consent to transfer uncompleted authorizations for visits from Lovelace to Heritage. Gentiva's consent shall specifically authorxxx Xxxxtage to bill and collect fees at Heritage's Gentiva contract rate. Heritaxx xill begin providing home healthcare service to such Other Patients on the Transition Date. If an Other Patient is not transitioned to Heritage's home healthcare service, Lovelace shall continue to provide home healthcare service to the xxxxxxx, provided that such patient is transitioned to another qualified home healthcare provider prior to the expiration of the Transition Period. If Lovelace is unable to provide home healthcare service to an Other Xxxxxxx pending transition, Lovelace shall subcontract with Heritage to provide such service xx xxxx Other Patients at the fee set forth in section 9.3 below. If Heritage is unable to provide home healthcare service to the Other Patient pending transition, Lovelace may subcontract with another home healthcare provider.
Sample 1
Other Patients. As of the Closing Date, MedCath Party shall prepare cut-off xxxxxxxx for all patients not covered by Section 10.1(b). MedCath Party shall be entitled to receive all amounts collected in respect of such cut-off xxxxxxxx. St. David’s shall remit to MedCath Party any amounts St. David’s receives after the Closing with respect to medical services rendered to such cost-based Transition Patients on or prior to the Closing, including any periodic interim payments or portions thereof applicable to the period on or prior to the Closing.
Sample 1
Other Patients. As of the Closing Date, Sellers shall prepare cutoff xxxxxxxx for all Transition Patients not covered by
Sample 1
AutoNDA by SimpleDocs

Related to Other Patients

  • Marking of Licensed Products To the extent commercially feasible and consistent with prevailing business practices, Company shall xxxx, and shall cause its Affiliates and Sublicensees to xxxx, all Licensed Products that are manufactured or sold under this Agreement with the number of each issued patent under the Patent Rights that applies to such Licensed Product.

  • Manufacture of Product Prior to commercialization of the Product, the Parties may, if appropriate for both parties, negotiate in good faith a manufacturing and supply agreement to provide for Licensor to fulfill the manufacturing requirements of Licensee for Product for sale in the European market. The cost of such manufacturing shall not be greater than * percent (*%) of the cost of any competitor cGMP contract manufacturing facility that proposes to manufacturer the Product for Licensee. * Confidential information has been omitted and filed confidentially with the Securities and Exchange Commission.

  • Manufacture of Products All Products marketed through Grantor's Web ------------------------- Site shall be manufactured, packaged, prepared, and shipped in accordance with the specifications and requirements described on Exhibit A hereto as it may be modified from time to time. Quality control standards relating to the Product's weight, color, consistency, micro-biological content, labeling and packaging are also set forth on Exhibit A. In the event that Exhibit A is incomplete, Products shall be manufactured and shipped in accordance with industry standards.

  • Patient Referrals Professional Business Manager and the Practice agree that the benefits to the Practice hereunder do not require, are not payment for, and are not in any way contingent upon the referral, admission, or any other arrangement for the provision of any item or service offered by Professional Business Manager to patients of the Practice in any facility, laboratory, center, or health care operation controlled, managed, or operated by Professional Business Manager.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Patient Records Upon termination of this Agreement, the New PC shall retain all patient dental records maintained by the New PC or the MSO in the name of the New PC. During the term of this Agreement, and thereafter, the New PC or its designee shall have reasonable access during normal business hours to the New PC's and the MSO's records, including, but not limited to, records of collections, expenses and disbursements as kept by the MSO in performing the MSO's obligations under this Agreement, and the New PC may copy any or all such records.

  • Third Party Contractors Tenant shall obtain and deliver to Landlord, Third Party Contractor’s certificates of insurance and applicable endorsements at least seven (7) business days prior to the commencement of work in or about the Premises by any vendor or any other third-party contractor (collectively, a “Third Party Contractor”). All such insurance shall (a) name Landlord as an additional insured under such party’s liability policies as required by Section 10.3.1 above and this Section 10.6, (b) provide a waiver of subrogation in favor of Landlord under such Third Party Contractor’s commercial general liability insurance, (c) be primary and any insurance carried by Landlord shall be excess and non-contributing, and (d) comply with Landlord’s minimum insurance requirements.

  • Development of Products (a) During the term of this Agreement, ViewRay may from time to time seek services from PEKO with respect to the development of certain Products that can be incorporated into the ViewRay Renaissance™ MRI-guided radiation therapy system. For each Program to be undertaken by PEKO pursuant to this Agreement, the parties will prepare a “Work Statement” and agree to said “Work Statement” in substantially the form attached as Attachment 1. Each Work Statement will describe: (i) the (i) services that PEKO will be responsible for providing to ViewRay and the deliverables that PEKO will be responsible for delivering to ViewRay (“Deliverable(s)”), (ii) delivery schedule for the Deliverables, (iii) pricing terms, (iv) work plan for the Program, and (v) ViewRay’s responsibilities in connection with the Program. Each Work Statement will be prepared based upon the requirements and information provided to PEKO by ViewRay. A separate Work Statement will be required for each Program; and each Work Statement will become subject to this Agreement only when mutually agreed and signed by ViewRay and PEKO.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!